权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of next-generation Intraocular lens combined with degradable drug delivery system toward prevention of Posterior Capsule Opacification

开发下一代人工晶状体结合可降解药物输送系统以预防后囊混浊

基本信息

批准号：
EP/S021485/1
负责人：
Aram Saeed
金额：
$ 48.61万
依托单位：
University of East Anglia
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2019
资助国家：
英国
起止时间：
2019 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=EP%2FS021485%2F1
关键词：
Development next generation Intraocular lens

项目摘要

A cataract is an ophthalmic disease in which a normal clear eye lens becomes cloudy or opaque, leading to a decrease in vision. The eye lens is responsible for focusing light and producing a clear image on the retina at the back of the eye. Cataracts are typically an ongoing process of healthy ageing, but seldom develop rapidly. Cataracts are responsible for more than 51% of the world's blindness. In 2010, the WHO estimated that 20 million people were suffering from cataracts and that the prevalence is estimated to double, reaching 40 million in 2020. There are more than three million cataract surgeries performed in the US annually. The prevalence of age-related cataract increases with age; the average age of a cataract patient is approximately 68 years in the US, and 50 and 65 in China and the UK, respectively.Cataracts are treated surgically by replacing the natural clouded lens with an artificial lens. During the procedure, the new lens is inserted into the remaining capsule, housing the new lens, and restoring visual acuity. Unfortunately, secondary blindness, also termed "secondary cataract" develops in a significant proportion of patients due to a wound-healing response known as posterior capsule opacification (PCO). Presently, the most common and effective treatment of PCO is laser capsulotomy, a procedure aimed to create a hole in the capsular bag to allow light to pass through again. However, this has many deleterious side effects and is also expensive for healthcare providers.To reduce the complication of cataract surgery, artificial lenses have been extensively modified since they were first developed in 1952 by Harold Ridley. The new lens designs have helped reduce the impact of PCO progression, but prevention of PCO remains elusive. Lens manufacturing companies and research academics are continuously searching for new designs and materials to address PCO. The overall aim of this proposal is to develop new lenses to restore high-quality vision following cataract surgery and prevent PCO formation. This research will unlock the potential of new lens design using emerging 3D printing technology as a new fabrication tool. This will have several advantages over the existing methods. The 3D printing method provides rapid prototype development of new lenses and takes weeks off the life cycle of lens development, expediting product development so lenses can reach patients quicker. There is also the potential to unlock new designs that would be impossible to produce by standard methods. These could potentially better the outcome of the surgery. This proposal also develops a drug delivery system to target the inflammation that occurs following surgery. The delivery system will enable controlled delivery of the drugs on-demand. Taken together, the new lens design, with local delivery of drugs, presents potential new therapies to treat cataract and prevent cataract complication. This proposal will be led by Dr Aram Saeed who is an expert in drug delivery, polymer chemistry and development of medical devices, in collaboration with Prof Michael Wormstone, a world-leading expert in cataract and the PCO condition.

白内障是一种眼科疾病，其中正常透明的眼睛透镜变得浑浊或不透明，导致视力下降。眼睛透镜负责聚焦光线并在眼睛后部的视网膜上产生清晰的图像。白内障通常是健康老龄化的持续过程，但很少迅速发展。白内障占世界失明人数的51%以上。2010年，世卫组织估计有2000万人患有白内障，预计患病率将翻一番，到2020年将达到4000万。每年在美国进行的白内障手术超过300万例。年龄相关性白内障的患病率随着年龄的增长而增加;白内障患者的平均年龄在美国约为68岁，在中国和英国分别为50岁和65岁。白内障的手术治疗是用人工透镜替换天然混浊的透镜。在手术过程中，将新的透镜插入剩余的囊内，容纳新的透镜，并恢复视力。不幸的是，继发性失明，也称为“继发性白内障”，由于被称为后囊膜混浊（PCO）的伤口愈合反应，在相当大比例的患者中发展。目前，PCO最常见和有效的治疗方法是激光囊切开术，该手术旨在在囊袋中创建一个孔以允许光线再次通过。然而，这会产生许多有害的副作用，而且对于医疗保健提供者来说也很昂贵。为了减少白内障手术的并发症，自1952年哈罗德·雷德利（Harold Ridley）首次开发人工晶状体以来，人工晶状体已经进行了广泛的改进。新的透镜设计有助于减少PCO进展的影响，但PCO的预防仍然难以实现。透镜制造公司和研究学者不断寻找新的设计和材料来解决PCO。该提案的总体目标是开发新的晶状体，以恢复白内障手术后的高质量视力并防止PCO形成。这项研究将利用新兴的3D打印技术作为新的制造工具，释放新透镜设计的潜力。与现有方法相比，这将具有几个优点。3D打印方法提供了新镜片的快速原型开发，并缩短了透镜开发的生命周期，加快了产品开发，使镜片可以更快地到达患者手中。还有可能解锁通过标准方法无法生产的新设计。这可能会改善手术的结果。该提案还开发了一种药物输送系统，以靶向手术后发生的炎症。该输送系统将能够按需控制药物的输送。总的来说，新的透镜设计，加上局部给药，为治疗白内障和预防白内障并发症提供了潜在的新疗法。该提案将由药物输送、聚合物化学和医疗器械开发方面的专家Aram Saeed博士领导，并与世界领先的白内障和PCO专家Michael Wormstone教授合作。